Bottom line
RXL vs PRHSX: the short answer
RXL (ProShares Ultra Health Care) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 69% by weight.
But PRHSX is far broader, holding 279 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.
PRHSX is cheaper at 0.83% vs 0.95% — a difference of $12 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
RXL vs PRHSX side by side
| RXL | PRHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | ProShares | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.95% | 0.83% |
| Annual cost per $10k | $95 | $83 |
| 10-yr cost on $10k (prospectus) | $1,305 | $1,025 |
| Max front load | None | — |
| 12b-1 fee | — | — |
| 1-yr return | +19.7% | +17.7% |
| 5-yr return (annualized) | +7.2% | +4.2% |
| 10-yr return (annualized) | +12.6% | +9.1% |
| Best quarter | +29.7% | +23.5% |
| Worst quarter | −28.9% | −15.8% |
| Net assets (fund) | $72.1M | $11.9B |
| Number of holdings | 70 | 279 |
| Portfolio turnover | 4% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RXL | PRHSX | Difference |
|---|---|---|---|
| 2025 | +19.7% | +17.7% | +2.0% |
| 2024 | −2.7% | +1.8% | −4.5% |
| 2023 | −3.2% | +3.1% | −6.3% |
| 2022 | −15.1% | −12.2% | −2.9% |
| 2021 | +47.8% | +13.3% | +34.6% |
| 2020 | +19.2% | +30.1% | −10.9% |
| 2019 | +38.9% | +29.1% | +9.8% |
| 2018 | +5.4% | +1.2% | +4.2% |
| 2017 | +46.0% | +28.0% | +18.1% |
| 2016 | −8.9% | −10.4% | +1.4% |
Source: Fund prospectus bar charts
Holdings overlap
16 of RXL's top 25 holdings also appear in PRHSX's top 25.
| Holding | RXL | PRHSX |
|---|---|---|
| Eli Lilly & Co. | 12.67% | 14.28% |
| Johnson & Johnson | 7.86% | 6.63% |
| AbbVie, Inc. | 5.57% | 5.10% |
| UnitedHealth Group, Inc. | 4.98% | 5.99% |
| Merck & Co., Inc. | 4.26% | 4.01% |
| Thermo Fisher Scientific, Inc. | 2.68% | 2.52% |
| Amgen, Inc. | 2.62% | 1.82% |
| Gilead Sciences, Inc. | 2.41% | 2.82% |
| Intuitive Surgical, Inc. | 2.18% | 1.87% |
| Abbott Laboratories | 2.15% | 1.89% |
| Bristol-Myers Squibb Co. | 1.68% | 2.11% |
| CVS Health Corp. | 1.67% | 0.94% |
| Danaher Corp. | 1.66% | 1.43% |
| Vertex Pharmaceuticals, Inc. | 1.64% | 2.28% |
| Stryker Corp. | 1.52% | 1.78% |
Source: SEC Form N-PORT
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between RXL and PRHSX?
Which is cheaper, RXL or PRHSX?
Should I own both RXL and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.